The Effect of the Parous Female and Young Male Donor on the Outcomes of GVHD Prophylaxis Underwent the Combined Treatment of ATG and PTCy for Haplo-HSCT: a Prospective, Multi-center, Cohort Study
This prospective, multicenter cohort study sponsored by Shanghai General Hospital aims to evaluate the impact of donor characteristics (parous female vs. young male) on GVHD prophylaxis outcomes in high-risk acute myeloid leukemia (AML) patients undergoing haplo-HSCT. The study targets a niche yet critical segment of the hematologic oncology market, particularly focusing on high-risk AML patients who have limited treatment options. The findings could influence clinical practices and donor selection criteria, potentially leading to improved patient outcomes and market positioning for therapies that enhance transplantation success rates. Given the increasing prevalence of AML and the demand for effective GVHD prophylaxis, successful outcomes may enhance the competitive landscape for related therapies and donor management strategies.
Indication: High-Risk Acute Myeloid Leukemia
Modality: combination therapy
Target: Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).
Sponsor: Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Source URL: ClinicalTrials.gov
Source updated: Jan 07, 2025
Ingested: Jun 18, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).
View original source fields
Condition raw: High-Risk Acute Myeloid Leukemia, Relapse And/or Refractory AML
Condition normalized: High-Risk Acute Myeloid Leukemia, Relapse And/or Refractory AML
Modality raw: combination therapy
Modality normalized: combination therapy
Target raw: Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).
Target normalized: Graft-versus-host disease (GVHD) prophylaxis through the combination of antithymocyte globulin (ATG) and post-transplant cyclophosphamide (PTCy) in haploidentical peripheral blood stem cell transplantation (haplo-HSCT).